No products in the cart.

Home / Human Rights / Finerenone receives positive CHMP opinion for EU-label extension for broad range of patients with chronic kidney disease and type 2 diabetes

Finerenone receives positive CHMP opinion for EU-label extension for broad range of patients with chronic kidney disease and type 2 diabetes

December 18, 2022 by Lezzie 0 comments Human Rights

Finerenone receives positive CHMP opinion for EU-label extension for broad range of patients with chronic kidney disease and type 2 diabetes

Berlin, December 16, 2022 – Bayer announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending a label extension for Kerendia™ (finerenone, 10 mg or 20 mg) to include results on cardiovascular outcomes from the Phase III FIGARO-DKD study…
Read More

PREVLETTER: Homeless can't be 'ignored, hidden, neglected'

NEXTAttacks on INEC: It's shameful that security personnel have not been able to bring any suspects to justice says Right Group